Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants
Status:
RECRUITING
Trial end date:
2024-04-23
Target enrollment:
Participant gender:
Summary
The objective of this clinical trial is to investigate the safety and tolerability of single ascending dose ACC017 tablets in Chinese healthy adult participants. This study aims to address the following major questions:
* Recommended dosage for ACC017 tablets used in phase Ib/IIa trial;
* The pharmacokinetic (PK) characteristics of single dose ACC017 tablets;
* The effect of food (FE) on the PK of ACC017 tablets;
* Drug-drug interactions (DDIs) when ACC017 tablets are co-administered with emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) tablets (II).